 So yesterday I came up here and I welcomed Genomic Medicine friends and family, so this is the Genomic Medicine die-hards, the last group remaining or standing. So we've introduced this topic at the last, at GM4, and I guess I have the slides here that we really want to begin to engage the international community in what we've been doing here in Genomic Medicine in the U.S. Okay, sorry, well, anyway, so why are we doing this? We're thinking about an international meeting, it's not obvious that we're, we're not insular, this is a global topic. I call them hubs, these are technology centers that have sprung up across almost every continent, across the globe to help enable genomic science to be done, but also to enable genomic medicine to be done, and genome sequencing is, of course, happening on human genomes across the globe. And there really isn't a forum of sorts that will really enable a global, a dialogue of the global, on a global scale of the many of the issues that we've covered, not just in this conference or in this workshop this week, but also in our prior one. And I also feel, and maybe this is not, maybe this is just me, that we have an opportunity to step into a leadership role, and as opposed to a potential watch or follow role, echoing some of what Dr. Sessions said yesterday about the kinds of viewpoints you could have on this. But we could lead and advance this as a global agenda, not just for genomic medicine, but clearly one of the topics that would be important to include in this is global health. So I'm just going to, I'm going to be very quick. We've discussed these yesterday, and also Dan just talked about the European Science Foundation that there are clearly groups that are countries and nations that are making investments in implementation and outcomes research and enabling genomic medicine to be applied to healthcare in Canada across several European sites. We heard about the UK strategy yesterday. We didn't mention this this time, but Israel is one of the, is trying to take a leadership role in the Middle East, and has had a series of meetings to develop a strategy that will be presented to their Ministry of Health. Israel is an interesting place because its entire healthcare system is managed by four HMOs, and includes a number of nationalities from the region, and the World Economic Forum that I just wanted to give you a brief update on. So I'm going to skip over these slides, because you've seen this, but the World Economic Forum initiated a new global agenda council or committee on personalized and precision health that was started last year. It doesn't have the broadest representation in the world. You can see the five or six countries that are represented in its current membership. But earlier this year funds and resources were approved to address three issues from the WEF that will be presented in part in Davos in 2014. One is a position paper on how personalized medicine and genomic medicine can address some areas of the global burden of disease, and that's a work that's being led by Dana Goldman at UCSF. The second is to get into the big data space and think about how big data can accelerate the science globally, and also to participate in some form yet to be decided on the concepts of data sharing, and the World Economic Forum has dedicated a consultant, A.T. Kearney, which is like a McKinsey group, to help really define the business proposition for data sharing and interoperability of databases, which has been something we've talked about here and various other forms. And lastly, best practices in regulatory reimbursement strategies for implementation of personalized and precision health. And this is an initiative that will be led by Peggy Hamburg from the FDA. So we'll see some movement at this, I think, important global platform for this, and I think it reflects, again, the timing of what we're talking about and bringing together a global community to really think about some of the genomic medicine implementation initiatives that we've discussed today and yesterday. So I don't have names, but these are some of the geographic regions and countries that we've thought about inviting leaders from. I think this is going to be, this is sort of a last plug to this group, to help us identify thought leaders and particularly individuals that are leading efforts to truly implement genomics and genomic medicines in various regions of the world. I certainly don't think that our working group is encyclopedic on this subject, so I'd encourage you to send me or Terry a message over the next few days, because our timing to get out invitations is becoming critical of individuals that you think would make a significant contribution. We're hoping to invite somewhere between 15 and 20, I think there's obviously some budget considerations, but 15 to 20 international participants and the kinds of people we're thinking about are both individuals that are sort of in government positions that can make policy decisions about funding as well as or in addition to scientific leaders that are really leading the charge on genomic medicine implementation in some of these areas. So that's a call to action, if you will, from this group. We've talked about some of what we might try to accomplish at this meeting, echoing some of what we did in our first meeting, GM1, with the U.S. community, I think really trying to think about what are some of the common barriers, synergies, and redundancies that we might illuminate by bringing these groups together. And importantly, can we then use that and channel that information into identifying possibilities for collaboration and maybe more effective implementation of genomic medicine projects. I think policy has got to be part of this discussion as well as there are myriad political as well as cultural environments that genomic medicine might be being deployed into and it's worth understanding what that diversity looks like and what some of the common policy and maybe diverse policy agendas might be. Interestingly, as we've talked about, we have a fragmented healthcare system in the U.S., but there are other places where it might be much more feasible to do some of what we're aspiring to do here, such as collaborating with places like Canada and the U.K. that have single-payer systems or city-states like Singapore where it might be more attractive to collaborate, if the goal is truly to generate evidence and proof of principle that genetics and genomics can make a difference both at the patient, provider, and the health system level. As Dan illustrated with what some of the European Science Foundation as well as the Canadian system is doing, I think we can explore maybe some of the lessons learned and best practices about engaging in public-private partnerships that we'd be enabling. And I put in here also a goal to think about some of the economic analyses that we could or economic data that we could capture to generate some of the economic arguments for genomic medicine as a strategy. So some of the possible outcomes that we might have from a meeting like this is a more of an international convening organization, pilot projects, standards, as we've talked about here. Can these be achieved globally? Again, from what Dan said, from the European Science Foundation's meeting, it sounds like that's going to be a significant challenge with the alphabet soup and a number of different types of IT and EMR systems, but it's something that we can at least address. And certainly education should be and workforce planning, which is a global challenge, I think, which should be on our agenda. So we aspire to seek information ahead of the meeting from all the participants to help us really maybe fill out this matrix in greater detail. So we have a landscape analysis of what the world is doing in this arena and we'll use that, I'm sure, to help us drive the agenda and discussion topics for the meeting. It will be here in Washington, most likely, I think, in September. The date will be finalized very shortly. And I think that is all I have to say. Actually, one other thing I wanted to say, which is that just as a reflection of this topic, again, is that this is a bit of an advertisement and a bit of a data point is that there's a Keystone meeting later in June in Stockholm, Sweden on human genomics and personalized medicine that I'm co-chairing with Kelly Frazier from UCSD. And I think, first of all, that this is one of the first Keystone meetings that I'm aware of that actually is on genomic and personalized medicine. I may be wrong about that, but it is one of the first and that it's being held in Europe, I think, is partly because a lot of the supporting foundations and industry groups that want to see this meeting take place are actually of European origin and they wanted to have the meeting in an accessible location for European investigators and attendees. And there are greater than 30 countries that are attending this meeting. There's over 250 registered attendees. So I think that's, again, a reflection of where some of the interest is in terms of the global community in this field. So again, if you'd like to attend that meeting, I think there's still time to register. A number of people in the room are actually speaking at it, but there's also quite a nice balance of United States and non-U.S. presenters at the meeting. So with that, I'll open this up for any questions, comments, or discussions. Les. Yes, Les. Who is representing the U.S. at that global action, the World Economic Forum? Oh, actually the U.S. has quite a large footprint on that committee. Francis Collins, Margaret Hamburg, to name two. Victor Zau is from Duke, is the chair. I'm on this committee, I think, to help Victor. And there's Charles Sawyers, Roger Chen, I'm blanking out a few of the names. But you can find the list of U.S. representatives on the World Economic Forum's website. Other comments for Jeff? All right. So we look forward to your input on possible attendees, but also, as we plan this meeting, the questions and topics are certainly open right now and certainly we'd appreciate your input. So like I said, email a message to either myself or Terri, and we'll thank you for your contribution to the meeting. Great. All right. I think at this point we have made it, as Jeff said, we're the die-hards. I do want to take a moment to thank Mike Heathcote, who did a fabulous job arranging this meeting and keeping us also. And we'll keep you apprised of plans for the next meeting and look forward to seeing you then. So thanks a lot.